A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

PHASE3RecruitingINTERVENTIONAL
Enrollment

2,400

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

March 23, 2033

Study Completion Date

December 29, 2034

Conditions
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast Neoplasms
Interventions
BIOLOGICAL

Sacituzumab tirumotecan

IV infusion

BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Rescue Medication

Participants receive rescue medication at the investigators discretion, per approved product label. Recommended rescue medications are histamine -1 (H1) receptor agonist, histamine-2 (H2) receptor antagonist, acetaminophen or equivalent, dexamethasone or equivalent infusion, or steroid mouthwash (dexamethasone or equivalent).

DRUG

Carboplatin

IV infusion

DRUG

Paclitaxel

IV infusion

DRUG

Doxorubicin

IV infusion

DRUG

Epirubicin

IV infusion

DRUG

Cyclophosphamide

IV infusion

DRUG

Capecitabine

Oral tablet

DRUG

Olaparib

Oral tablet

Trial Locations (58)

333

RECRUITING

Chang Gung Medical Foundation-Linkou Branch ( Site 1906), Taoyuan District

407

RECRUITING

Taichung Veterans General Hospital ( Site 1904), Taichung

2196

RECRUITING

Sandton Oncology Medical Group (Pty) Ltd ( Site 4900), Sandton

6045

RECRUITING

CANCERCARE LANGENHOVEN DRIVE ONCOLOGY CENTRE ( Site 4907), Port Elizabeth

10048

RECRUITING

National Taiwan University Hospital ( Site 1900), Taipei

13620

RECRUITING

Seoul National University Bundang Hospital ( Site 1801), Kyonggi-do

18009

RECRUITING

"COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 5207)", Cherkasy

21202

RECRUITING

Mercy Medical Center - Baltimore ( Site 0015), Baltimore

25011

RECRUITING

CNE Regional clinical oncology center of Kirovograd regional Council ( Site 5203), Kropyvnytsky

33013

RECRUITING

Bioresearch Partner ( Site 0072), Hialeah

37208

RECRUITING

Nashville General Hospital ( Site 0017), Nashville

46237

RECRUITING

Franciscan Health ( Site 0077), Indianapolis

46804

RECRUITING

Fort Wayne Medical Oncology and Hematology ( Site 0084), Fort Wayne

58013

RECRUITING

"Municipal Enterprise Bukovinian сlinical oncology сenter ( Site 5208)", Chernivtsi

58201

RECRUITING

Altru Health System ( Site 0057), Grand Forks

68516

RECRUITING

Cancer Partners of Nebraska ( Site 0068), Lincoln

71103

RECRUITING

Louisiana State University Health Sciences Shreveport ( Site 0053), Shreveport

76018

RECRUITING

CNCE Precarpathian Clinical Oncologic Center ( Site 5201), Ivano-Frankivsk

77030

RECRUITING

Oncology Consultants P.A. ( Site 0073), Houston

80218

RECRUITING

Saint Joseph Hospital ( Site 0062), Denver

81501

RECRUITING

Intermountain Health St. Mary's Regional Hospital ( Site 0054), Grand Junction

89502

RECRUITING

Renown Regional Medical Center ( Site 0041), Reno

92835

RECRUITING

Providence Medical Foundation ( Site 0080), Fullerton

98405

RECRUITING

Northwest Medical Specialties, PLLC ( Site 0067), Tacoma

200000

RECRUITING

Fudan University Shanghai Cancer Center ( Site 2209), Shanghai

210036

RECRUITING

Jiangsu Province Hospital ( Site 2216), Nanjing

250013

RECRUITING

Jinan Central Hospital ( Site 2249), Jinan

250117

RECRUITING

Shandong Cancer Hospital ( Site 2205), Jinan

310017

RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine ( Site 2212), Hangzhou

310022

RECRUITING

Zhejiang Cancer Hospital ( Site 2211), Hangzhou

311599

RECRUITING

Zhejiang Provincial People's Hospital ( Site 2215), Hangzhou

330025

RECRUITING

The Third Hospital Of Nanchang ( Site 2218), Nanchang

361009

RECRUITING

The First Affiliated hospital of Xiamen University-Breast Surgery ( Site 2224), Xiamen

430000

RECRUITING

Wuhan Union Hospital ( Site 2239), Wuhan

450000

RECRUITING

Henan Cancer Hospital ( Site 2238), Zhengzhou

529030

RECRUITING

Jiangmen Center Hospital ( Site 2243), Jiangmen

530201

RECRUITING

Guangxi Medical University Affiliated Tumor Hospital ( Site 2223), Nanning

618099

RECRUITING

Deyang City People's Hospital ( Site 2244), Deyang

641099

RECRUITING

The Second People's Hospital of Neijiang ( Site 2242), Neijiang

3109601

RECRUITING

Rambam Health Care Campus ( Site 4400), Haifa

5265601

RECRUITING

Sheba Medical Center ( Site 4401), Ramat Gan

04092

RECRUITING

New England Cancer Specialists ( Site 0051), Westbrook

T4000IHE

RECRUITING

Clínica Mayo de Urgencias Médicas Cruz Blanca S.R.L ( Site 6006), San Miguel de Tucumán

01009

RECRUITING

MEDI-K ( Site 6400), Guatemala City

01010

RECRUITING

CELAN,S.A ( Site 6401), Guatemala City

RECRUITING

INTEGRA Cancer Institute ( Site 6404), Guatemala City

RECRUITING

Onco Go, S.A ( Site 6402), Guatemala City

01015

RECRUITING

Asociacion Española de Beneficencia ( Site 6403), Guatemala City

Unknown

RECRUITING

Hong Kong United Oncology Centre ( Site 1304), Jordan

RECRUITING

Queen Mary Hospital ( Site 1300), Pokfulam

RECRUITING

Prince of Wales Hospital ( Site 1301), Shatin

003-0804

RECRUITING

National Hospital Organization Hokkaido Cancer Center ( Site 2300), Sapporo

565-0871

RECRUITING

The University of Osaka Hospital ( Site 2314), Suita

142-8666

RECRUITING

Showa Medical University Hospital ( Site 2306), Shinagawa

260-8717

RECRUITING

Chiba Cancer Center ( Site 2303), Chiba

960-1295

RECRUITING

Fukushima Medical University Hospital ( Site 2301), Fukushima

540-0006

RECRUITING

National Hospital Organization Osaka National Hospital ( Site 2315), Osaka

03080

RECRUITING

Seoul National University Hospital ( Site 1806), Seoul

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY